Prognostic value of pretreatment neutrophil count in metastatic renal cell carcinoma: a systematic review and meta-analysis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.2133226742998
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58–v68. doi:10.1093/annonc/mdw32827664262
   PubMed Web of Science ®Google Scholar
• Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193–205. doi:10.1016/j.ctrv.2007.12.00118313224
   PubMed Web of Science ®Google Scholar
• Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008;15(2):3954–3966.18405442
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–2540. doi:10.1200/JCO.1999.17.8.253010561319
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature0132212490959
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Kowalewska M, Nowak R, Chechlinska M. Implications of cancer-associated systemic inflammation for biomarker studies. Biochim Biophys Acta. 2010;1806(2):163–171. doi:10.1016/j.bbcan.2010.06.00220600631
   PubMed Web of Science ®Google Scholar
• Minardi D, Scartozzi M, Montesi L, et al. Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. Springerplus. 2015;4:255. doi:10.1186/s40064-015-1036-126085975
   PubMedGoogle Scholar
• Steffens S, Kohler A, Rudolph R, et al. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer. 2012;12:399. doi:10.1186/1471-2407-12-39922958305
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-011229684
   PubMed Web of Science ®Google Scholar
• Koo KC, Lee KS, Cho KS, Rha KH, Hong SJ, Chung BH. Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio. Int Urol Nephrol. 2016;48(6):985–992. doi:10.1007/s11255-016-1252-926946137
   PubMed Web of Science ®Google Scholar
• Okada F. Inflammation-related carcinogenesis: current findings in epidemiological trends, causes and mechanisms. Yonago Acta Med. 2014;57(2):65–72.25324587
   PubMed Web of Science ®Google Scholar
• Fox P, Hudson M, Brown C, et al. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer. 2013;109(1):147–153. doi:10.1038/bjc.2013.30023778526
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi:10.1186/1745-6215-8-1617555582
   PubMed Web of Science ®Google Scholar
• Artac M, Coskun HS, Korkmaz L, et al. Using interferon alfa before tyrosine kinase inhibitors may increase survival in patients with metastatic renal cell carcinoma: a Turkish oncology group (TOG) study. Clin Genitourin Cancer. 2016;14(4):e347–e353. doi:10.1016/j.clgc.2016.04.02127236771
   PubMed Web of Science ®Google Scholar
• Santoni M, Buti S, Conti A, et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol. 2015;10(4):517–522. doi:10.1007/s11523-014-0356-325559290
   PubMed Web of Science ®Google Scholar
• You D, Jeong IG, Song C, et al. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era. Jpn J Clin Oncol. 2015;45(1):96–102. doi:10.1093/jjco/hyu17125341544
   PubMed Web of Science ®Google Scholar
• Poprach A, Pavlik T, Melichar B, et al. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urol Oncol. 2014;32(4):488–495. doi:10.1016/j.urolonc.2013.09.01124321257
   PubMed Web of Science ®Google Scholar
• Santoni M, De Giorgi U, Iacovelli R, et al. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer. 2013;109(7):1755–1759. doi:10.1038/bjc.2013.52224008663
   PubMed Web of Science ®Google Scholar
• Kroeger N, Xie W, Lee JL, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the international mRCC database consortium criteria. Cancer. 2013;119(16):2999–3006. doi:10.1002/cncr.2815123696129
   PubMed Web of Science ®Google Scholar
• Azuma T, Matayoshi Y, Nagase Y, Oshi M. Neutrophil number after interferon-alfa treatment is an independent predictive marker of overall survival in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2012;10(3):180–184. doi:10.1016/j.clgc.2012.03.00622608529
   PubMed Web of Science ®Google Scholar
• Lee JL, Park I, Park K, et al. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. J Cancer Res Clin Oncol. 2012;138(4):687–693. doi:10.1007/s00432-012-1148-822237457
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799. doi:10.1200/JCO.2008.21.480919826129
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Reitz M. Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma. Cancer Biother Radiopharm. 2008;23(1):129–134. doi:10.1089/cbr.2007.042918298337
   PubMed Web of Science ®Google Scholar
• Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006;24(13):1997–2005. doi:10.1200/JCO.2005.03.959416648500
   PubMed Web of Science ®Google Scholar
• Peccatori J, Barkholt L, Demirer T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer. 2005;104(10):2099–2103. doi:10.1002/cncr.2147716220555
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003;88(3):348–353. doi:10.1038/sj.bjc.660076812569375
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi:10.1007/s10654-010-9491-z20652370
   PubMed Web of Science ®Google Scholar
• Gu L, Li H, Chen L, et al. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016;7(22):31926–31942. doi:10.18632/oncotarget.787626942464
   PubMedGoogle Scholar
• Na N, Yao J, Cheng C, et al. Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors. Oncotarget. 2016;7(28):44039–44046. doi:10.18632/oncotarget.983627270655
   PubMedGoogle Scholar
• Hu K, Lou L, Ye J, Zhang S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ Open. 2015;5(4):e006404. doi:10.1136/bmjopen-2014-006404
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Bukowski R, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer. 2013;108(12):2470–2477. doi:10.1038/bjc.2013.23623695024
   PubMed Web of Science ®Google Scholar
• Stegenga ME, van der Crabben SN, Blumer RM, et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood. 2008;112(1):82–89. doi:10.1182/blood-2007-11-12172318316629
   PubMed Web of Science ®Google Scholar
• Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. 2006;6(7):541–550. doi:10.1038/nri184116799473
   PubMed Web of Science ®Google Scholar
• Ashtekar AR, Saha B. Poly’s plea: membership to the club of APCs. Trends Immunol. 2003;24(9):485–490.12967672
   PubMed Web of Science ®Google Scholar
• Pekarek LA, Starr BA, Toledano AY, Schreiber H. Inhibition of tumor growth by elimination of granulocytes. J Exp Med. 1995;181(1):435–440. doi:10.1084/jem.181.1.4357807024
   PubMed Web of Science ®Google Scholar
• Tazawa H, Okada F, Kobayashi T, et al. Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol. 2003;163(6):2221–2232. doi:10.1016/S0002-9440(10)63580-814633597
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013;218(11):1402–1410. doi:10.1016/j.imbio.2013.06.00323891329
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol. 2013;228(7):1404–1412. doi:10.1002/jcp.2426023065796
   PubMed Web of Science ®Google Scholar
• Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest. 2010;120(4):1151–1164. doi:10.1172/JCI3722320237412
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–194. doi:10.1016/j.ccr.2009.06.01719732719
   PubMed Web of Science ®Google Scholar
• Dumitru CA, Lang S, Brandau S. Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol. 2013;23(3):141–148. doi:10.1016/j.semcancer.2013.02.00523485549
   PubMed Web of Science ®Google Scholar
• Ebrahem Q, Chaurasia SS, Vasanji A, et al. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol. 2010;176(1):496–503. doi:10.2353/ajpath.2010.08064219948826
   PubMed Web of Science ®Google Scholar
• Gasparini C, Menegazzi R, Patriarca P, Dri P. Evidence that elastase is the TNF-R75 shedding enzyme in resting human polymorphonuclear leukocytes. FEBS Lett. 2003;553(3):360–364.14572651
   PubMed Web of Science ®Google Scholar
• Wada Y, Yoshida K, Tsutani Y, et al. Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines. Oncol Rep. 2007;17(1):161–167.17143494
   PubMed Web of Science ®Google Scholar
• Houghton AM, Rzymkiewicz DM, Ji H, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010;16(2):219–223. doi:10.1038/nm.208420081861
   PubMed Web of Science ®Google Scholar
• Lopez-Lago MA, Posner S, Thodima VJ, Molina AM, Motzer RJ, Chaganti RS. Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene. 2013;32(14):1752–1760. doi:10.1038/onc.2012.20122665059
   PubMed Web of Science ®Google Scholar
• Shang K, Bai YP, Wang C, et al. Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS One. 2012;7(12):e51848. doi:10.1371/journal.pone.005184823272179
   PubMed Web of Science ®Google Scholar
• Chen YL, Chen SH, Wang JY, Yang BC. Fas ligand on tumor cells mediates inactivation of neutrophils. J Immunol. 2003;171(3):1183–1191.12874204
   PubMed Web of Science ®Google Scholar
• Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol. 2011;186(2):807–815. doi:10.4049/jimmunol.100148321148040
   PubMed Web of Science ®Google Scholar
• Hubert P, Heitzmann A, Viel S, et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res. 2011;71(15):5134–5143. doi:10.1158/0008-5472.CAN-10-422221697279
   PubMed Web of Science ®Google Scholar
• Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2011;20(3):300–314. doi:10.1016/j.ccr.2011.08.01221907922
   PubMed Web of Science ®Google Scholar